# DIFFERENT **TYPES OF** VACCINES

There are several types of vaccines currently under development for COVID-19, each with different potential strengths and weaknesses.

## NUCLEIC ACID VACCINES

- New type of vaccine that uses fragments of mRNA or DNA to produce an adaptive immune response through the host cells, producing copies of that target antigen
- Elicits both antibody and cytotoxic T-lymphocyte responses
- Can scale up and produce quickly
- Expensive & booster doses likely needed
- >90% efficacy in initial phase 3 data from Moderna, Pfizer

### Vaccines in development


- Moderna
- Pfizer Inovio
- CureVac
- Sanofi/Translate Bio

# **INACTIVATED VACCINES**

- Uses a killed version of the virus to generate immunity
- Elicits neutralizing antibodies without a cell-mediated response
- > Can be safely given to immunocompromised patients
- Proven vaccine technology already in use for several diseases (hepatitis A, influenza, polio, rabies)
- Booster doses likely needed

## Vaccines in development

- > Chinese Academy of
  - Medical Sciences
- > Wuhan Institute of Biologic Projects
- > Sinovac




## VIRAL VECTOR

- Uses modified non-coronaviruses (adenoviruses, vesicular stomatitis virus) expressing SARS-CoV-2 spike protein
- Elicits both antibody and cytotoxic T-lymphocyte responses
- Potential safety concerns in immunocompromised patients
- Host immunity to the viral vector may reduce vaccine efficacv
- Single dose possible
- Can quickly produce

## Vaccines in development

- Johnson & Johnson
- CanSinoBIO
- AstraZeneca
- Merck



# PROTEIN

- Uses recombinant viral proteins to induce immune response  $\geq$
- Elicits neutralizing antibodies without a cell-mediated ≻ response
- > Can be safely given to immunocompromised patients
- Proven vaccine technology already in use for many diseases (eg, hepatitis B, HPV, pertussis, herpes zoster)
- Booster doses likely needed

### Vaccines in development

- ➢ Sanofi/GSK
- Novavax
- Walter Reed Army Institute of Research (WRAIR)





The authors gratefully acknowledge the assistance of Dr. Kayvon Modjarrad and Dr. Julie Ake (WRAIR) in the creation of this graphic.

- RNA

